drugset / Trial / NCT06773403
Upadacitinib for Prurigo Nodularis
NaSingle-groupOpen-labelTreatment
Summary
A single center, open-label study of 25 subjects to assess 24 weeks upadacitinib in patients with moderate-to-severe prurigo nodularis.
Timeline
- Start
- 2024-04-09
- Primary completion
- 2025-06-06
- Completion
- 2025-06-06
Outcome
Outcome not reported
Stopped (Enrollment): “There was not a big enough patient population to meet recruitment goals”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Upadacitinib | Small molecule | 15 mg | — |
| Subject | Upadacitinib | Small molecule | 30 mg | — |